Rigel Pharmaceuticals Secures VEPPANU License from Arvinas and Pfizer Ahead of August Commercial Launch

With a $70 million upfront payment now settled and an August commercial availability target on the calendar, Rigel Pharmaceuticals has closed its exclusive global license for VEPPANU (vepdegestrant), placing GMP readiness, supply chain continuity, and post-approval pharmacovigilance squarely on the company's near-term operational agenda.

The agreement, effective June 11, 2026, grants Rigel rights to develop, manufacture, and commercialize vepdegestrant globally. The $70 million payment is split evenly between licensors Arvinas, Inc. and Pfizer Inc., consistent with disclosed deal terms. Closing followed early termination of the Hart-Scott-Rodino waiting period and satisfaction of standard antitrust conditions.

VEPPANU carries FDA approval for adults with estrogen receptor-positive (ER+)/HER2-negative, ESR1-mutated advanced or metastatic breast cancer, confirmed by an FDA-authorized companion diagnostic, with disease progression on at least one prior line of endocrine therapy. As a PROTAC-class selective estrogen receptor degrader, the molecule represents a mechanistic category that manufacturing and QA teams will need to treat with particular process validation rigor, degrader biologics carry distinct analytical characterization requirements compared with conventional small molecules.

For plant heads and supply chain leads, the compressed timeline between license close and commercial launch leaves limited runway for technology transfer verification, batch release protocol alignment, and distribution network qualification under 21 CFR Part 211. QA directors inheriting post-marketing surveillance obligations will also need to operationalize the product's established safety profile: serious adverse reactions occurred in 9% of trial patients, with QTc prolongation, hepatic injury, and fracture among the flagged events requiring active monitoring infrastructure at launch.

The August target date will serve as the first measurable checkpoint for Rigel's manufacturing and regulatory execution under the new agreement.

Source: Rigel Pharmaceuticals, Inc. press release via PR Newswire, June 16, 2026.